Literature DB >> 19711348

Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma.

Dietmar Abraham1, Karin Zins, Mouldy Sioud, Trevor Lucas, Romana Schäfer, E Richard Stanley, Seyedhossein Aharinejad.   

Abstract

The molecular mechanisms of tumor-host interactions that render neuroblastoma (NB) cells highly invasive are unclear. Cancer cells upregulate host stromal cell colony-stimulating factor-1 (CSF-1) production to recruit tumor-associated macrophages (TAMs) and accelerate tumor growth by affecting extracellular matrix remodeling and angiogenesis. By coculturing NB with stromal cells in vitro, we showed the importance of host CSF-1 expression for macrophage recruitment to NB cells. To examine this interaction in NB in vivo, mice bearing human CSF-1-expressing SK-N-AS and CSF-1-negative SK-N-DZ NB xenografts were treated with intratumoral injections of small interfering RNAs directed against mouse CSF-1. Significant suppression of both SK-N-AS and SK-N-DZ NB growth by these treatments was associated with decreased TAM infiltration, matrix metalloprotease (MMP)-12 levels and angiogenesis compared to controls, while expression of tissue inhibitors of MMPs increased following mouse CSF-1 blockade. Furthermore, Tie-2-positive and -negative TAMs recruited by host CSF-1 were identified in NB tumor tissue by confocal microscopy and flow cytometry. However, host-CSF-1 blockade prolonged survival only in CSF-1-negative SK-N-DZ NB. These studies demonstrated that increased CSF-1 production by host cells enhances TAM recruitment and NB growth and that the CSF-1 phenotype of NB tumor cells adversely affects survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19711348      PMCID: PMC3222589          DOI: 10.1002/ijc.24859

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  52 in total

Review 1.  Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.

Authors:  John Condeelis; Jeffrey W Pollard
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

2.  The macrophage colony-stimulating factor, CSF-1.

Authors:  E R Stanley
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

3.  Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.

Authors:  Qun Wang; Sharon Diskin; Eric Rappaport; Edward Attiyeh; Yael Mosse; Daniel Shue; Eric Seiser; Jayanti Jagannathan; Suzanne Shusterman; Manisha Bansal; Deepa Khazi; Cynthia Winter; Erin Okawa; Gregory Grant; Avital Cnaan; Huaqing Zhao; Nai-Kong Cheung; William Gerald; Wendy London; Katherine K Matthay; Garrett M Brodeur; John M Maris
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

4.  Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.

Authors:  Patrick Paulus; E Richard Stanley; Romana Schäfer; Dietmar Abraham; Seyedhossein Aharinejad
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

5.  Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.

Authors:  Ebba Palmberg; John Inge Johnsen; Janna Paulsson; Helena Gleissman; Malin Wickström; Margareta Edgren; Arne Ostman; Per Kogner; Magnus Lindskog
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

6.  Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway.

Authors:  Karin Zins; Dietmar Abraham; Mouldy Sioud; Seyedhossein Aharinejad
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome.

Authors:  Yuan Xue; Piotr Religa; Renhai Cao; Anker Jon Hansen; Franco Lucchini; Bernt Jones; Yan Wu; Zhenping Zhu; Bronislaw Pytowski; Yuxiang Liang; Weide Zhong; Paolo Vezzoni; Björn Rozell; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-18       Impact factor: 11.205

8.  Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.

Authors:  Lars Johan Nissen; Renhai Cao; Eva-Maria Hedlund; Zongwei Wang; Xing Zhao; Daniel Wetterskog; Keiko Funa; Ebba Bråkenhielm; Yihai Cao
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 9.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

10.  Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.

Authors:  Mary Anna Venneri; Michele De Palma; Maurilio Ponzoni; Ferdinando Pucci; Cristina Scielzo; Erika Zonari; Roberta Mazzieri; Claudio Doglioni; Luigi Naldini
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

View more
  30 in total

Review 1.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  Macrophage diversity enhances tumor progression and metastasis.

Authors:  Bin-Zhi Qian; Jeffrey W Pollard
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

Review 3.  Differential macrophage programming in the tumor microenvironment.

Authors:  Brian Ruffell; Nesrine I Affara; Lisa M Coussens
Journal:  Trends Immunol       Date:  2012-01-23       Impact factor: 16.687

4.  Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulations.

Authors:  Marja Lohela; Amy-Jo Casbon; Aleksandra Olow; Lynn Bonham; Daniel Branstetter; Ning Weng; Jeffrey Smith; Zena Werb
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

5.  Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes.

Authors:  Matthew W Webb; Jianping Sun; Michael A Sheard; Wei-Yao Liu; Hong-Wei Wu; Jeremy R Jackson; Jemily Malvar; Richard Sposto; Dylan Daniel; Robert C Seeger
Journal:  Int J Cancer       Date:  2018-05-07       Impact factor: 7.396

6.  Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrin-mediated signaling in murine models.

Authors:  Richard C Godby; Yascha W Van Den Berg; Ramprasad Srinivasan; Robert Sturm; David Y Hui; Stephen F Konieczny; Bruce J Aronow; Evgeny Ozhegov; Wolfram Ruf; Henri H Versteeg; Vladimir Y Bogdanov
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

Review 7.  More than the genes, the tumor microenvironment in neuroblastoma.

Authors:  Lucia Borriello; Robert C Seeger; Shahab Asgharzadeh; Yves A DeClerck
Journal:  Cancer Lett       Date:  2015-11-17       Impact factor: 8.679

8.  Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.

Authors:  Jason H Stafford; Takahisa Hirai; Lei Deng; Sophia B Chernikova; Kimiko Urata; Brian L West; J Martin Brown
Journal:  Neuro Oncol       Date:  2015-11-03       Impact factor: 12.300

9.  Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas.

Authors:  Jacky Yeung; Vesal Yaghoobi; Danielle Miyagishima; Matthew D Vesely; Tianxiang Zhang; Ti Badri; Ala Nassar; Xue Han; Miguel F Sanmamed; Mark Youngblood; Matthieu Peyre; Michel Kalamarides; David L Rimm; Murat Gunel; Lieping Chen
Journal:  Neuro Oncol       Date:  2021-11-02       Impact factor: 12.300

Review 10.  Tumor-associated macrophages: from mechanisms to therapy.

Authors:  Roy Noy; Jeffrey W Pollard
Journal:  Immunity       Date:  2014-07-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.